Orexo Added to Russell Global Index
Uppsala, Sweden – June 30, 2014 – Orexo AB (NASDAQ OMX Stockholm: ORX and US OTCQX: ORXOY) today announced that the Company’s stock has been added to the Russell Global Index. The inclusion is part of the annual reconstitution of the entire Russell family of indexes that took place on June 27, 2014, following the close of market.
“Being added to this global index is a reflection of the progress Orexo has made within the last year and should help to increase the Company’s visibility internationally, particularly in the US,” said Nikolaj Sørensen, President and CEO of Orexo.
The Russell Global Indexes reflect the performance of over 10,000 securities in 47 countries.
Selection for inclusion in these indexes is based upon market capitalization and other market factors relating to a company and its stock. Membership in these indexes is updated annually, and remains in place for one year.
Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.2 trillion in assets currently are benchmarked to Russell Indexes.
About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States. The company is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The ZUBSOLV® sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap.
For further information, please contact:
Henrik Juuel, EVP and CFO
Tel: +46 (0)722-20 94 77, E-mail: email@example.com